Symbol | Exchange | Currency |
|---|
Investing.com - Keros (NASDAQ: KROS) reported first quarter EPS of $-1.09, $0.02 better than the analyst estimate of $-1.11. Revenue for the quarter came in at $0.00 versus the...
Investing.com – U.S. stocks were lower after the close on Friday, as losses in the Oil & Gas, Technology and Basic Materials sectors led shares lower. At the close in NYSE, the...
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company’s lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
| Average | 96.67 (+129.45% Upside) |
| High | 120.00 |
| Low | 75.00 |
| Price | 42.13 |
| No. of Analysts | 6 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Sell | Sell | Sell |
| Technical Indicators | Strong Sell | Buy | Strong Sell | Strong Sell | Neutral |
| Summary | Strong Sell | Neutral | Strong Sell | Strong Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 195.28 | 197.33 | 194.42 | +1.40 | +0.72% | 109.50M | NASDAQ | |||
| 162.36 | 162.47 | 161.27 | +1.59 | +0.99% | 46.76M | NASDAQ | |||
| 61.85 | 62.09 | 61.66 | -0.01 | -0.02% | 8.35M | NYSE | |||
| 207.84 | 208.09 | 202.82 | +2.49 | +1.21% | 22.53M | NASDAQ | |||
| 100.89 | 101.15 | 99.78 | -0.50 | -0.49% | 32.74M | NASDAQ | |||
| 284.05 | 284.46 | 281.48 | +3.54 | +1.26% | 24.97M | NASDAQ | |||
| 40.38 | 40.49 | 40.25 | +0.13 | +0.32% | 12.49M | NYSE | |||
| 97.88 | 99.53 | 97.25 | +1.79 | +1.86% | 58.34M | NASDAQ | |||
| 102.00 | 103.04 | 101.01 | +1.75 | +1.75% | 51.96M | NASDAQ | |||
| 162.67 | 164.50 | 162.41 | +0.54 | +0.33% | 1.16M | NASDAQ | |||
| 273.83 | 274.99 | 271.02 | +3.99 | +1.48% | 35.62M | NASDAQ | |||
| 8.15 | 8.38 | 8.05 | -0.07 | -0.85% | 20.57M | NYSE | |||
| 101.32 | 101.61 | 100.29 | -0.58 | -0.57% | 24.17M | NASDAQ | |||
| 46.51 | 47.32 | 46.02 | -0.19 | -0.41% | 12.10M | NYSE | |||
| 51.43 | 51.68 | 51.13 | +0.26 | +0.51% | 11.42M | NASDAQ |